Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice.
Pérez-Ruiz E, Jiménez-Castro J, Berciano-Guerrero MA, Valdivia J, Estalella-Mendoza S, Toscano F, Rodriguez de la Borbolla Artacho M, Garrido-Siles M, Martínez-Bautista MJ, Villatoro Roldan R, Rivas-Ruiz F, Nogales-Fernández E, Morales C, Pérez-Valderrama B, De la Cruz-Merino L, Rueda A.
Pérez-Ruiz E, et al. Among authors: martinez bautista mj.
Clin Transl Oncol. 2020 Oct;22(10):1778-1785. doi: 10.1007/s12094-020-02315-9. Epub 2020 Feb 24.
Clin Transl Oncol. 2020.
PMID: 32096143